All In Biotech

NDA 022110 · Apotex

Vibativ

Telavancin Hydrochloride · Intravenous

Novel

Last checked: Nov 20, 2026Latest source record: Jul 7, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Sep 11, 2009

Approved uses

2

Original approval plus efficacy supplements

Registered trials

15

5 Phase 3, 1 recruiting

FAERS reports

120

91 serious, 12 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN HABP/VABP PATIENTS WITH PRE-EXISTING MODERATE OR SEVERE RENAL IMPAIRMENT, NEPHROTOXICITY, POTENTIAL ADVERSE DEVELOPMENTAL OUTCOMES Patients with pre-existing moderate/severe renal impairment (CrCl ≤ 50 mL/min) who were treated with VIBATIV for hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP) had increased mortality observed versus vancomycin. Use of VIBATIV in patients with pre-existing moderate/severe renal impairment (CrCl ≤ 50 mL/min) should be considered only when the anticipated benefit to the patient outweighs the potential risk [see Warnings and Precautions ( 5.1 , 8.4 )]. Nephrotoxicity: New onset or worsening renal impairment has occurred. Monitor renal function in all patients [see Warnings and Precautions ( 5.3 )] . Embryofetal Toxicity: VIBATIV may cause fetal harm. In animal reproduction studies,...

What it is approved for

From the label in effect Dec 19, 2025.

VIBATIV is a lipoglycopeptide antibacterial drug indicated for the treatment of the following infections in adult patients caused by designated susceptible bacteria: Complicated skin and skin structure infections (cSSSI) ( 1.1 ) Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus . VIBATIV should be reserved for use when alternative treatments are not suitable. ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of VIBATIV and other antibacterial drugs VIBATIV should only be used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. 1.1 Complicated Skin and Skin Structure Infections VIBATIV is indicated for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus) , or Enterococcus faecalis (vancomycinsusceptible isolates only). 1.2 HABP/VABP VIBATIV is indicated for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Staphylococcus aureus (both methicillin-susceptible and -resistant isolates). VIBATIV should be reserved for use when alternative treatments are not suitable. 1.3 Usage Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram-negative organisms. Appropriate specimens for bacteriological examination should be obtained in order to...

Mechanism: Telavancin is an antibacterial drug [ see Clinical Pharmacology ( 12.4 ) ].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • VIBATIV · TELAVANCIN HYDROCHLORIDE EQ 250MG BASE/VIAL · POWDER, INTRAVENOUS · Discontinued
  • VIBATIV · TELAVANCIN HYDROCHLORIDE EQ 750MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Telavancin" as an intervention, any sponsor and status, largest first.

All 15 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use19
  • renal failure acute15
  • blood creatinine increased12
  • nausea12
  • chills9
  • thrombocytopenia7
  • diarrhoea6
  • dyspnoea6
  • leukopenia6
  • renal failure6
  • vomiting6
  • acute kidney injury5

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20092
201033
201145
20125
20144
20161
201823
20194
20251
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vibativ (Telavancin HCl)

2024 spending

$553K

Beneficiaries

33

137 claims

Per beneficiary

$16,770

$33.54 per unit

View as table
YearSpending
2020$0
2021$628,663
2022$618,855
2023$781,599
2024$553,402

Part B: Vibativ (Telavancin HCL) · HCPCS J3095

2024 spending

$1.1M

Beneficiaries

138

1,362 claims

Per beneficiary

$7,729

2024 ASP limit $7.12 per unit

View as table
YearSpending
2020$1,871,453
2021$1,353,073
2022$1,223,977
2023$1,683,613
2024$1,066,665

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 47 on PubMed

Sponsor: Apotex

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.